Consun Pharmaceutical adjusts share capital with buyback and option exercises
Consun Pharmaceutical Group Limited reported a decrease in its total issued shares to 847,939,307 as of September 30, 2025, down from 852,865,707 at the close of the preceding month. This change was primarily due to the cancellation of 5,195,000 ordinary shares repurchased between June 16, 2025, and July 18, 2025, at a weighted average price of HK$ 10.3655 per share.
The company also issued 268,600 new shares through the exercise of share options under its scheme adopted on December 2, 2013. These exercises occurred throughout September 2025, with prices ranging from HK$ 3.7083 to HK$ 4.01 per share, raising a total of HK$ 1,071,836.4 for the company. Despite the option exercises, the cancellation of repurchased shares resulted in a net reduction of 4,926,400 issued shares.
The authorized share capital remains unchanged at 5,000,000,000 ordinary shares with a par value of HK$ 0.1 each, totaling HK$ 500,000,000. These movements reflect strategic adjustments in Consun Pharmaceutical’s capital structure.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Consun Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime